Hansoh Pharmaceutical Group Company Limited
3692
Rang in aandelen
#909
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Aandeelprijs
$4.34
Marktkapitalisatie
$26.34B
Verandering (1 dag)
-1.22%
Verandering (1 jaar)
-5.95%
Land
CN
Handel Hansoh Pharmaceutical Group Company Limited (3692)
Categorie
Healthcare
Winst voor Hansoh Pharmaceutical Group Company Limited (3692)
Winst in Jun 2026 TTM: $1.14B
Volgens de meest recente financiële verslagen van Hansoh Pharmaceutical Group Company Limited bedraagt de huidige winst van het bedrijf $1.14B. In 2023 behaalde het bedrijf een winst van $532.05M, een stijging ten opzichte van de winst van 2022, die $427.44M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Hansoh Pharmaceutical Group Company Limited van 2016 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.14B | 63.74% |
| 2024 | $696.69M | 30.94% |
| 2023 | $532.05M | 24.47% |
| 2022 | $427.44M | -17.68% |
| 2021 | $519.22M | 9.48% |
| 2020 | $474.28M | 10.05% |
| 2019 | $430.96M | 28.37% |
| 2018 | $335.73M | 13.01% |
| 2017 | $297.07M | 14.31% |
| 2016 | $259.87M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 54.69% |
IN
|
